334 related articles for article (PubMed ID: 15943473)
1. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
6. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
7. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
8. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
[TBL] [Abstract][Full Text] [Related]
9. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
Hunt JT; Mitt T; Borzilleri R; Gullo-Brown J; Fargnoli J; Fink B; Han WC; Mortillo S; Vite G; Wautlet B; Wong T; Yu C; Zheng X; Bhide R
J Med Chem; 2004 Jul; 47(16):4054-9. PubMed ID: 15267243
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
16. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.
Kubo K; Shimizu T; Ohyama S; Murooka H; Iwai A; Nakamura K; Hasegawa K; Kobayashi Y; Takahashi N; Takahashi K; Kato S; Izawa T; Isoe T
J Med Chem; 2005 Mar; 48(5):1359-66. PubMed ID: 15743179
[TBL] [Abstract][Full Text] [Related]
17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
20. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Hilberg F; Roth GJ; Krssak M; Kautschitsch S; Sommergruber W; Tontsch-Grunt U; Garin-Chesa P; Bader G; Zoephel A; Quant J; Heckel A; Rettig WJ
Cancer Res; 2008 Jun; 68(12):4774-82. PubMed ID: 18559524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
